Video
Author(s):
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.
Ide-Cel Generates Favorable PFS Outcomes in R/R Multiple Myeloma With Lower Tumor Burden
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
Enhancing the Referral Process for Genetic Testing Represents Key Next Step in Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes
Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL
Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma